Thaper, Daksh
Vahid, Sepideh
Kaur, Ramandeep
Kumar, Sahil
Nouruzi, Shaghayegh
Bishop, Jennifer L.
Johansson, Martin
Zoubeidi, Amina
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (201410GSD-352466-230421)
Article History
Received: 1 June 2018
Accepted: 7 November 2018
First Online: 23 November 2018
Competing Interests
: Martin Johansson is the CEO of Glactone Pharma Development AB which provided galiellalactone. Other authors declare no conflict of interest.